{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:48:48Z","timestamp":1773290928338,"version":"3.50.1"},"reference-count":79,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005247","name":"University of British Columbia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005247","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","onlinecjc.ca","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.cjca.2015.02.013","type":"journal-article","created":{"date-parts":[[2015,2,19]],"date-time":"2015-02-19T01:46:27Z","timestamp":1424310387000},"page":"1282-1292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pharmacologic Options for the Management of Systolic Heart Failure: Examining Underlying Mechanisms"],"prefix":"10.1016","volume":"31","author":[{"given":"G.B. John","family":"Mancini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan G.","family":"Howlett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Borer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter P.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mandeep R.","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Pfeffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl","family":"Swedberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Claude","family":"Tardif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2015.02.013_bib1","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.cjca.2013.12.013","article-title":"Assessing the burden of hospitalized and community-care heart failure in Canada","volume":"30","author":"Blais","year":"2014","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2015.02.013_bib2","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.cardfail.2007.04.006","article-title":"Systolic and diastolic heart failure: differences and similarities","volume":"13","author":"Chatterjee","year":"2007","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.cjca.2015.02.013_bib3","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1503\/cmaj.111958","article-title":"Trends in the incidence and outcomes of heart failure in Ontario, Canada: 1997 to 2007","volume":"184","author":"Yeung","year":"2012","journal-title":"CMAJ"},{"key":"10.1016\/j.cjca.2015.02.013_bib4","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/eurjhf\/hfq185","article-title":"Trends in heart failure care: has the incident diagnosis of heart failure shifted from the hospital to the emergency department and outpatient clinics?","volume":"13","author":"Ezekowitz","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2015.02.013_bib5","first-page":"e28","article-title":"Heart disease and stroke statistics\u20132014 update: a report from the American Heart Association","volume":"129","author":"Go","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2015.02.013_bib6","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/HHF.0b013e318291329a","article-title":"Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association","volume":"6","author":"Heidenreich","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cjca.2015.02.013_bib7","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.cjca.2012.10.007","article-title":"The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure","volume":"29","author":"McKelvie","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2015.02.013_bib8","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2015.02.013_bib9","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2015.02.013_bib10","unstructured":"McKelvie RS, Moe GW, Ezekowitz JA, et\u00a0al. Supplemental material for The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure. Available at: http:\/\/www.onlinecjc.ca\/cms\/attachment\/2006113535\/2027683951\/mmc1.pdf. Accessed February 2,\u00a02015."},{"key":"10.1016\/j.cjca.2015.02.013_bib11","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.2174\/1381612811319170012","article-title":"Non-ACE pathway-induced angiotensin II production","volume":"19","author":"Uehara","year":"2013","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.cjca.2015.02.013_bib12","first-page":"1429","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group","volume":"316","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2015.02.013_bib13","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators","volume":"325","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2015.02.013_bib14","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/01.CIR.86.2.431","article-title":"Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators","volume":"86","author":"Konstam","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2015.02.013_bib15","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2015.02.013_bib16","first-page":"821","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators","volume":"342","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2015.02.013_bib17","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","article-title":"A\u00a0clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group","volume":"333","author":"Kober","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2015.02.013_bib18","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(00)02212-1","article-title":"Long-term ACE inhibitor therapy in patients with heart failure or left ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group","volume":"355","author":"Flather","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2015.02.013_bib19","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1161\/01.CIR.103.13.1746","article-title":"Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy","volume":"103","author":"Gibbs","year":"2001","journal-title":"Circulation"},{"issue":"suppl J","key":"10.1016\/j.cjca.2015.02.013_bib20","doi-asserted-by":"crossref","first-page":"J10","DOI":"10.1093\/eurheartj\/sui057","article-title":"The role of angiotensin II receptor blockers in the management of heart failure","volume":"7","author":"McMurray","year":"2005","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.cjca.2015.02.013_bib21","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1161\/01.CIR.98.25.2911","article-title":"Preserved vasodilator effect of bradykinin in dogs with heart failure","volume":"98","author":"Su","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2015.02.013_bib22","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/archinte.1993.00410080011002","article-title":"Tissue renin-angiotensin system in myocardial hypertrophy and failure","volume":"153","author":"Dzau","year":"1993","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cjca.2015.02.013_bib23","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1161\/01.CIR.96.4.1173","article-title":"Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure","volume":"96","author":"Grassi","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2015.02.013_bib24","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/0735-1097(95)00484-X","article-title":"Enalaprilat augments arterial and cardiopulmonary baroreflex control of sympathetic nerve activity in patients with heart failure","volume":"27","author":"Dibner-Dunlap","year":"1996","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2015.02.013_bib25","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1161\/01.CIR.98.25.2842","article-title":"Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure","volume":"98","author":"Hornig","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2015.02.013_bib26","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1161\/01.CIR.102.3.351","article-title":"Improvement of endothelial function by chronic angiotensin-converting enzyme inhibition in heart failure: role of nitric oxide, prostanoids, oxidant stress, and bradykinin","volume":"102","author":"Varin","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2015.02.013_bib27","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/S0735-1097(99)00495-7","article-title":"Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure","volume":"34","author":"Gullestad","year":"1999","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2015.02.013_bib28","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1161\/01.CIR.96.2.442","article-title":"Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators","volume":"96","author":"Vaughan","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2015.02.013_bib29","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1161\/01.CIR.99.23.2983","article-title":"Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure","volume":"99","author":"Goodfield","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2015.02.013_bib30","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1161\/01.CIR.95.7.1930","article-title":"Improvement of alveolar-capillary membrane diffusing capacity with enalapril in chronic heart failure and counteracting effect of aspirin","volume":"95","author":"Guazzi","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2015.02.013_bib31","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.ejheart.2004.02.002","article-title":"A\u00a0meta-analysis of the effect of angiotensin-converting enzyme inhibitors on functional capacity in patients with symptomatic left ventricular systolic dysfunction","volume":"6","author":"Abdulla","year":"2004","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2015.02.013_bib32","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1093\/eurheartj\/ehs257","article-title":"Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice","volume":"33","author":"Zannad","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2015.02.013_bib33","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0735-1097(02)01755-2","article-title":"Radial, carotid and aortic distensibility in congestive heart failure: effects of high-dose angiotensin-converting enzyme inhibitor or low-dose association with angiotensin type 1 receptor blockade","volume":"39","author":"Giannattasio","year":"2002","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6 suppl","key":"10.1016\/j.cjca.2015.02.013_bib34","doi-asserted-by":"crossref","first-page":"S465","DOI":"10.1054\/jcaf.2002.129289","article-title":"Relation between left ventricular remodeling and clinical outcomes in heart failure patients with left ventricular systolic dysfunction","volume":"8","author":"Udelson","year":"2002","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.cjca.2015.02.013_bib35","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2015.02.013_bib36","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2015.02.013_bib37","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2015.02.013_bib38","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2015.02.013_bib39","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"issue":"suppl 1","key":"10.1016\/j.cjca.2015.02.013_bib40","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1388-9842(00)80082-3","article-title":"Current treatment in hospital based outpatient heart failure clinics: the Canadian CHF Clinics Network initial experience","volume":"2","author":"Arnold","year":"2000","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2015.02.013_bib41","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A\u00a0randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2015.02.013_bib42","first-page":"Cd003040","article-title":"Angiotensin receptor blockers for heart failure","volume":"4","author":"Heran","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cjca.2015.02.013_bib43","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/S0735-1097(01)01683-7","volume":"38","author":"Hunt","year":"2001","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2015.02.013_bib44","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/S0195-668X(03)00477-9","article-title":"Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure","volume":"24","author":"McKelvie","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2015.02.013_bib45","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2015.02.013_bib46","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2015.02.013_bib47","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2015.02.013_bib48","doi-asserted-by":"crossref","first-page":"16633","DOI":"10.1074\/jbc.M109.008748","article-title":"Aldosterone stimulates elastogenesis in cardiac fibroblasts via mineralocorticoid receptor-independent action involving the consecutive activation of G alpha13, c-Src, the insulin-like growth factor-I receptor, and phosphatidylinositol 3-kinase\/Akt","volume":"284","author":"Bunda","year":"2009","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.cjca.2015.02.013_bib49","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","article-title":"Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators","volume":"102","author":"Zannad","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2015.02.013_bib50","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1136\/hrt.2003.017368","article-title":"Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment","volume":"90","author":"Macdonald","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.cjca.2015.02.013_bib51","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1097\/HJH.0b013e3282e9a72d","article-title":"Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure","volume":"25","author":"Shah","year":"2007","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.cjca.2015.02.013_bib52","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/S0735-1097(01)01243-8","article-title":"Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure","volume":"37","author":"Yee","year":"2001","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2015.02.013_bib53","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1161\/01.CIR.0000068340.96506.0F","volume":"107","author":"Hayashi","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2015.02.013_bib54","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1161\/CIRCHEARTFAILURE.112.000074","article-title":"Impact of mineralocorticoid receptor antagonists on changes in cardiac structure and function of left ventricular dysfunction: a meta-analysis of randomized controlled trials","volume":"6","author":"Li","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cjca.2015.02.013_bib55","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group","volume":"334","author":"Packer","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2015.02.013_bib56","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2015.02.013_bib57","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jama.283.10.1295","article-title":"Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR\/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group","volume":"283","author":"Hjalmarson","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2015.02.013_bib58","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2015.02.013_bib59","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/eurjhf\/hfs060","article-title":"Heart rate achieved or beta-blocker dose in patients with chronic heart failure: which is the better target?","volume":"14","author":"Cullington","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2015.02.013_bib60","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1161\/CIRCRESAHA.111.245092","article-title":"Treatment of chronic heart failure with \u03b2-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology","volume":"109","author":"Bristow","year":"2011","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2015.02.013_bib61","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.amjcard.2007.11.023","article-title":"Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers","volume":"101","author":"Flannery","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2015.02.013_bib62","doi-asserted-by":"crossref","first-page":"784","DOI":"10.7326\/0003-4819-150-11-200906020-00006","article-title":"Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure","volume":"150","author":"McAlister","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2015.02.013_bib63","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1093\/eurheartj\/ehr483","article-title":"The beat goes on: on the importance of heart rate in chronic heart failure","volume":"33","author":"Swedberg","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2015.02.013_bib64","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00392-010-0207-x","article-title":"Heart rate reduction in cardiovascular disease and therapy","volume":"100","author":"Reil","year":"2011","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.cjca.2015.02.013_bib65","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1056\/NEJM199001113220206","article-title":"Cardiomyopathy of overload. A major determinant of prognosis in congestive heart failure","volume":"322","author":"Katz","year":"1990","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2015.02.013_bib66","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1161\/CIRCHEARTFAILURE.113.000429","article-title":"Association of heart rate at hospital discharge with mortality and hospitalizations in patients with heart failure","volume":"7","author":"Habal","year":"2014","journal-title":"Circ Heart Fail"},{"issue":"suppl","key":"10.1016\/j.cjca.2015.02.013_bib67","first-page":"485","article-title":"Raised heart rate at discharge after acute heart failure is an independent predictor of one-year mortality","volume":"33","author":"Logeart","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2015.02.013_bib68","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jchf.2013.08.005","article-title":"The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial","volume":"1","author":"Greene","year":"2013","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cjca.2015.02.013_bib69","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jacc.2011.12.044","article-title":"Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program","volume":"59","author":"Castagno","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2015.02.013_bib70","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0140-6736(10)61259-7","article-title":"Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial","volume":"376","author":"Bohm","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2015.02.013_bib71","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs033","volume":"14","author":"McMurray","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2015.02.013_bib72","unstructured":"National Heart Foundation of Australia. Guidelines for the prevention, detection, and management of chronic heart failure in Australia. Available at: http:\/\/www.heartfoundation.org.au\/SiteCollectionDocuments\/Chronic_Heart_Failure_Guidelines_2011.pdf. Accessed February 2,\u00a02015."},{"key":"10.1016\/j.cjca.2015.02.013_bib73","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1093\/eurheartj\/ehs259","article-title":"Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study","volume":"33","author":"Borer","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2015.02.013_bib74","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1093\/eurheartj\/ehr343","article-title":"Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study","volume":"32","author":"Ekman","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2015.02.013_bib75","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.2165\/00003495-200464160-00003","article-title":"Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease","volume":"64","author":"DiFrancesco","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.cjca.2015.02.013_bib76","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1159\/000362086","article-title":"Ivabradine: heart rate and left ventricular function","volume":"128","author":"Ferrari","year":"2014","journal-title":"Cardiology"},{"key":"10.1016\/j.cjca.2015.02.013_bib77","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1093\/eurheartj\/ehr311","article-title":"Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy","volume":"32","author":"Tardif","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2015.02.013_bib78","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/FJC.0b013e31823e5e01","article-title":"Heart rate reduction induced by the if current inhibitor ivabradine improves diastolic function and attenuates cardiac tissue hypoxia","volume":"59","author":"Fang","year":"2012","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.cjca.2015.02.013_bib79","first-page":"e131","article-title":"Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure","volume":"9","author":"Langenickel","year":"2012","journal-title":"Drug Discov Today"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X15001270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X15001270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T14:26:27Z","timestamp":1668695187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X15001270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":79,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0828282X15001270"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2015.02.013","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacologic Options for the Management of Systolic Heart Failure: Examining Underlying Mechanisms","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2015.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}